Physician
Pathology
Dr. Dipen Maru, MD
|
|
Give Review
Dipen Maru is an expert in the field of Pathology. He graduated from University Hospital - University of Cincinnati College of Medicine. Dipen Maru is a published doctor as well. He has 46 publications published. The latest was: RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. He is registered with Medicare and accepts Medicare payments.
Publications
- Oncologic Outcomes of Extended Robotic Resection for Rectal Cancer.
- The consensus molecular subtypes of colorectal cancer.
- Endoscopic Ultrasound Estimates for Tumor Depth at the Gastroesophageal Junction Are Inaccurate: Implications for the Liberal Use of Endoscopic Resection.
- A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer.
- Geographic Distribution of Regional Metastatic Nodes Affects the Outcome of Trimodality-Eligible Patients with Esophageal Adenocarcinoma.
- Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors.
- Association between KRAS mutation and lung metastasis in advanced colorectal cancer.
- Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer.
- RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated with Chemotherapy Before Resection of Colorectal Liver Metastases.
- Importance of Surveillance and Success of Salvage Strategies After Definitive Chemoradiation in Patients With Esophageal Cancer.
- Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer.
- Signet Ring Cells in Esophageal Adenocarcinoma Predict Poor Response to Preoperative Chemoradiation.
- Clinicopathologic Characteristics and Gene Expression Analyses of Non-KRAS 12/13, RAS-Mutated Metastatic Colorectal Cancer.
- Hippo coactivator YAP1 upregulates SOX9 and endows stem-like properties to esophageal cancer cells.
- Tumor Location Is a Strong Predictor of Tumor Progression and Survival in T2 Gallbladder Cancer: An International Multicenter Study.
- Reply to Can quantified pathologic response assessed as residual tumor burden be a promising staging system for patients with rectal cancer treated with chemoradiation...
- Preoperative Radiation Therapy With Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Cancer: A Phase 1 Trial.
- Locoregional Failure Rate After Preoperative Chemoradiation of Esophageal Adenocarcinoma and the Outcomes of Salvage Strategies.
- RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases.
- FXR Silencing in Human Colon Cancer by DNA methylation and KRAS Signaling.
- ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients.
- Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after ...
- The Influence of Histopathologic Tumor Viability on Long-term Survival and Recurrence Rates Following Neoadjuvant Therapy for Esophageal Adenocarcinoma.
- Incidence of Brain Metastases after Trimodality Therapy in Patients with Esophageal or Gastroesophageal Cancer: Implications for Screening and Surveillance.
- Propensity-Based Matching between Esophagogastric Cancer Patients Who Had Surgery and Who Declined Surgery after Preoperative Chemoradiation.
- Margin Status Remains an Important Determinant of Survival After Surgical Resection of Colorectal Liver Metastases in the Era of Modern Chemotherapy.
- Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis ...
- Predictive Biomarkers for Bevacizumab: Are We There Yet?
- Loss of TGF-? Adaptor ?2SP Activates Notch Signaling and SOX9 Expression in Esophageal Adenocarcinoma.
- Endothelial Cells Promote the Colorectal Cancer Stem Cell Phenotype through a Soluble Form of Jagged-1.
- Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases.
- Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer.
- Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepate...
- Salvage Esophagectomy After Failed Definitive Chemoradiation for Esophageal Adenocarcinoma.
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.
- MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.
- Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival.
- Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases.
- Esophageal tumor length is independently associated with long-term survival.
- Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cance...
- Novel endoscopic application of a new flexible-fiber CO2 laser for esophageal mucosal ablation in a porcine model.
- Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
- High-resolution imaging in Barrett's esophagus: a novel, low-cost endoscopic microscope.
- Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
- RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.
Doctors Specialties
- Pathology
Accepted Insurances
Education
-
University of Texas MD Anderson Cancer Center -
University Hospital - University of Cincinnati College of Medicine -
M.P. Shah Medical College
Hospital
-
University of Texas M.D. Anderson Cancer Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1679688832 |
| Last Name Of The Provider | MARU |
| First Name Of The Provider | DIPEN |
| View All |
Similar Doctors
|
|
Dr. Mary V. Gresik, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mojghan Amrikachi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roupen H. Dekmezian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joe G. Ford, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nathan E. Lee, MD |
|
|
Dr. Guilin Tang, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Kristine Konopka, MD
This Doctor is OpenDoctor Recommended.
|